Skip to main content
. 2021 Dec 22;2(1):23–36. doi: 10.1016/j.fmre.2021.11.032

Fig. 1.

Fig 1

Engineering of the multi-faceted OMV chassis for simultaneous antigen display and antibody binding. (a) Schematic of the OMV platform engineering and vaccine preparation, (b) and (c) DLS analysis (b) and TEM examination (c) of OMV-SpyC/SPAb. Scale bar, 50 nm. (d) and (e) Western blot assay to detect ClyA-SpyC-3Cmyc (d) and ClyA-SPAb-3Flag (e) levels in OMV-SpyC/SPAb using anti-Cmyc and anti-Flag antibodies, respectively. (f) One-step western blot assay to analyze the antibody binding function of ClyA-SPAb-3Flag using the HRP-conjugated Rat IgG antibody (Rat IgG-HRP). (g) The observation of αDEC205 antibody binding on OMV-SpyC/SPAb using TEM. αDEC205 antibody was labeled with 10 nm gold nanoparticles. Scale bar, 20 nm. (h) Western blot assay to verify the rapid binding between ClyA-SpyC-3Cmyc and SpyT-HA (ClyA-SpyC-SpyT-HA, ∼60 kDa) using an anti-HA antibody. MW, molecular weight.